Puma Biotechnology

2,495

$13.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.36 (-2.58%) Today

-$0.39 (-2.87%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell PBYI and other stocks, options, ETFs, and crypto commission-free!

About PBYI

Puma Biotechnology Inc Common Stock, also called Puma Biotechnology, is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. Read More The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

CEO

Alan H. Auerbach

Employees

272

Headquarters

Los Angeles, California

Founded

2010

Market Cap

542.73M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

2.21M

High Today

$14.50

Low Today

$12.15

Open Price

$12.60

Volume

2.94M

52 Week High

$43.90

52 Week Low

$6.26

Collections

PBYI News

Reuters13h

Edited Transcript of PBYI earnings conference call or presentation 20-Feb-20 9:30pm GMT

Q4 2019 Puma Biotechnology Inc Earnings Call Los Angeles Feb 21, 2020 (Thomson StreetEvents) -- Edited Transcript of Puma Biotechnology Inc earnings conference

ReutersFeb 20

BRIEF-Puma Biotechnology Q4 Loss Per Share Of $0.29

Feb 20 (Reuters) - Puma Biotechnology Inc: * PUMA BIOTECHNOLOGY REPORTS FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS * Q4 ADJUSTED NON-GAAP EARNINGS PER SHA

158